ENTX · Entera Bio Ltd.
$2.75
+0.25 (+10.00%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 7, 2026
The latest filing states the doubt was alleviated.
“Following the closing of the private placement and receipt of the related net proceeds, management concluded that substantial doubt about the Company’s ability to continue as a going concern no longer exists.”View the 10-Q filed Aug 7, 2026
Market Cap
$465.75M
Shares
173.14M
Volume · Oct 9
1.58M
Avg daily vol (3M)
1.8M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.50
Open$2.48
Day$2.45–2.52
52W close$1.00–3.92
Avg vol 30d440K
Short int2.4M · 1.4% float · 5.2d
Short vol93%
Last earningsApr 20, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 7
Up next
Next earnings call
May 11, 2028
Est · unconfirmed
· in 83 wks
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$17.03M
Trailing 12 months
Revenue growth YoY
-76.8%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
7.4
Trailing earnings · reciprocal yield 13.5%
FCF yield
-2.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.7%
Year over year · more shares
Price change (1Y)
+32.8%
Trailing year
Short interest
1.4%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
−14%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
51%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+95%
trailing
YTD return
+29%
this year
Relative strength
+86%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.39% of float · ▲ +87.5% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 3-yr high, broad support
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
−77%
Y/Y
Gross margin
0%
contracting
EPS growth
0%
Y/Y
Free cash flow
$-7.5M
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
−14%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
51%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.39% of float · ▲ +87.5% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $3 · 51%
Range high $4
vs 200-day avg +38%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTX
this stock
Entera Bio Ltd.
|
$465.75M | +28.9% | -76.8% | — | 1.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
27
- % held
- 6.2%
- Net QoQ
- +2.9M sh
- Top holder
- Knoll Capital Management,…
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTX | -13.5% | -10.4% | +95.3% | -14.1% | +28.9% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -14.8% | -12.5% | +86.3% | -15.6% | +15.4% |